| 5.05 -0.23 (-4.36%) | 07-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 6.28 |
1-year : | 7.33 |
| Resists | First : | 5.38 |
Second : | 6.28 |
| Pivot price | 4.83 |
|||
| Supports | First : | 4.54 |
Second : | 4.03 |
| MAs | MA(5) : | 4.88 |
MA(20) : | 4.73 |
| MA(100) : | 5.68 |
MA(250) : | 6.63 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 69.3 |
D(3) : | 56.9 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 10.98 | Low : | 3.59 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ LXEO ] has closed below upper band by 23.5%. Bollinger Bands are 46.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 5.39 - 5.41 | 5.41 - 5.44 |
| Low: | 4.89 - 4.92 | 4.92 - 4.94 |
| Close: | 5 - 5.05 | 5.05 - 5.1 |
Lexeo Therapeutics, Inc. is a genetic medicine firm currently in the clinical development phase, dedicated to addressing both inherited and acquired medical conditions. Its robust pipeline features several gene therapy candidates. These include LX2006, an AAVrh10-based therapy aimed at treating cardiomyopathy linked to Friedreich's ataxia (FA); LX2020, another AAVrh10-based candidate targeting arrhythmogenic cardiomyopathy; LX2021, designed for DSP cardiomyopathy; and LX2022, which focuses on hypertrophic cardiomyopathy (HCM) stemming from TNNI3 mutations. Furthermore, Lexeo is advancing LX1001, an AAVrh10-based gene therapy, alongside LX1020 and LX1021, all intended for individuals homozygous for APOE4. Additionally, LX1004 is under development to treat CLN2 Batten disease. Established in 2017, the company's headquarters are located in New York, New York.
Wed, 01 Jul 2026
Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock - Investing.com
Wed, 01 Jul 2026
RSU grant and tax-cover share sale by Lexeo (LXEO) chief financial officer - Stock Titan
Wed, 01 Jul 2026
Lexeo Therapeutics (LXEO) COO reports stock award and small tax-related sale - Stock Titan
Wed, 01 Jul 2026
Lexeo Therapeutics (LXEO) CMO awarded 55K shares and sells 22K to cover RSU taxes - Stock Titan
Wed, 01 Jul 2026
Lexeo Therapeutics (LXEO) CEO logs RSU grant and tax-driven share sale - Stock Titan
Mon, 29 Jun 2026
Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70 - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 79 (M) |
| Shares Float | 48 (M) |
| Held by Insiders | 0.6 (%) |
| Held by Institutions | 115.4 (%) |
| Shares Short | 14,090 (K) |
| Shares Short P.Month | 13,210 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.11 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -32.5 % |
| Return on Equity (ttm) | -54.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.8 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.24 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -98 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -4.51 |
| PEG Ratio | 0 |
| Price to Book value | 1.61 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.05 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|